Abstract
Background The structural environment of urban slums, including physical, demographic and socioeconomic attributes, renders inhabitants more vulnerable to SARS-CoV-2 infection. Yet, little is known about the specific determinants that contribute to high transmission within these communities.
Methods and findings We performed a serosurvey of an established cohort of 2,035 urban slum residents from the city of Salvador, Brazil between November 2020 and February 2021, following the first COVID-19 pandemic wave in the country. We identified high SARS-CoV-2 seroprevalence (46.4%, 95% confidence interval [CI] 44.3-48.6%), particularly among female residents (48.7% [95% CI 45.9-51.6%] vs. 43.2% [95% CI 39.8-46.6%] among male residents), and among children (56.5% [95% CI 52.3-60.5%] vs. 42.4% [95% CI 39.9-45.0%] among adults). In multivariable models that accounted for household-level clustering, the odds ratio for SARS-CoV-2 seropositivity among children was 1.96 (95% CI 1.42-2.72) compared to adults aged 30-44 years. Adults residing in households with children were more likely to be seropositive; this effect was particularly prominent among individuals with age 30-44 and 60 years or more. Women living below the poverty threshold (daily per capita household income <$1.25) and those who were unemployed were more likely to be seropositive.
Conclusions During a single wave of the COVID-19 pandemic, cumulative incidence as assessed by serology approached 50% in a Brazilian urban slum population. In contrast to observations from industrialized countries, SARS-CoV-2 incidence was highest among children, as well as women living in extreme poverty. These findings emphasize the need for targeted interventions that provide safe environments for children and mitigate the structural risks posed by crowding and poverty for the most vulnerable residents of urban slum communities.
Competing Interest Statement
A.I.K serves as an expert panel member for Reckitt Global Hygiene Institute, scientific advisory board member for Revelar Biotherapeutics and a consultant for Tata Medical and Diagnostics and Regeneron Pharmaceuticals, and has received grants from Merck, Regeneron Pharmaceuticals and Tata Medical and Diagnostics for research related to COVID-19, all of which are outside the scope of the submitted work. Other authors declare no conflict of interest.
Funding Statement
This work was supported by grants from the National Institutes of Health (R01 AI052473, U01AI088752, R01 TW009504 and R25 TW009338 to A.I.K.), UK Medical Research Council (MR/T029781/1 to F.C.), Wellcome Trust (102330/Z/13/Z; 218987/Z/19/Z to F.C.), Brazilian Coordination for the Improvement of Higher Education Personnel (CAPES88881.130749/2016-01 to G.S.R.), Brazilian National Council for Scientific and Technological Development (CNPq 440891/2016-7 and research scholarship to G.S.R.), Bahia Foundation for Research Support (FAPESB SUS0019/2021 and PET0022/2016 to G.S.R.), and the Sendas Family Fund at the Yale School of Public Health (A.I.K.). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Brazilian National Commission for Ethics in Research and the Yale University Human Research Protection Program gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Funding statement This work was supported by grants from the National Institutes of Health (R01 AI052473, U01AI088752, R01 TW009504 and R25 TW009338 to A.I.K.), UK Medical Research Council (MR/T029781/1 to F.C.), Wellcome Trust (102330/Z/13/Z; 218987/Z/19/Z to F.C.), Brazilian Coordination for the Improvement of Higher Education Personnel (CAPES88881.130749/2016- 01 to G.S.R.), Brazilian National Council for Scientific and Technological Development (CNPq 440891/2016-7 and research scholarship to G.S.R.), Bahia Foundation for Research Support (FAPESB SUS0019/2021 and PET0022/2016 to G.S.R.), and the Sendas Family Fund at the Yale School of Public Health (A.I.K.). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Conflicts of Interest: A.I.K serves as an expert panel member for Reckitt Global Hygiene Institute, scientific advisory board member for Revelar Biotherapeutics and a consultant for Tata Medical and Diagnostics and Regeneron Pharmaceuticals, and has received grants from Merck, Regeneron Pharmaceuticals and Tata Medical and Diagnostics for research related to COVID- 19, all of which are outside the scope of the submitted work. Other authors declare no conflict of interest.
Data Availability
All data produced in the present study are available upon reasonable request to the authors
